輝瑞因潛在肝臟損傷停止減肥藥測試Pfizer Ends Testing of Obesity Pill After Possible Liver Injury

動脈網

2025/04/16

TUESDAY, April 15, 2025 — Pfizer has stopped developing a once-daily pill to treat obesity after a person in a clinical trial showed signs of a possible liver injury.2025年4月15日，星期二——輝瑞公司停止了一種每日一次的治療...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2527425919"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2527425919\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2527425919?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-04-16 01:35","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2527425919","market":"us","top_or_hot":-1,"title":"輝瑞因潛在肝臟損傷停止減肥藥測試Pfizer Ends Testing of Obesity Pill After Possible Liver Injury","media":"動脈網","content":"<div>\n<p>TUESDAY, April 15, 2025 — Pfizer has stopped developing a once-daily pill to treat obesity after a person in a clinical trial showed signs of a possible liver injury.2025年4月15日，星期二——輝瑞公司停止了一種每日一次的治療...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504160136159738d6c8&s=b\">網頁鏈接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>輝瑞因潛在肝臟損傷停止減肥藥測試Pfizer Ends Testing of Obesity Pill After Possible Liver Injury</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n輝瑞因潛在肝臟損傷停止減肥藥測試Pfizer Ends Testing of Obesity Pill After Possible Liver Injury\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">動脈網</strong><span class=\"h-time small\">2025-04-16 01:35</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>TUESDAY, April 15, 2025 — Pfizer has stopped developing a once-daily pill to treat obesity after a person in a clinical trial showed signs of a possible liver injury.2025年4月15日，星期二——輝瑞公司停止了一種每日一次的治療...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504160136159738d6c8&s=b\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504160136159738d6c8&s=b\">動脈網</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999002232.USD","symbol_name":"Allianz Global High Payout USD","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504160136159738d6c8&s=b","article_id":"2527425919","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504160136159738d6c8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2527425919","pubTimestamp":1744738500,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"Pfizer will now stop all testing of danuglipron, including its use with other drugs for obesity treatment. However, the company said it still plans to work on other obesity treatments that are in earlier stages of research.輝瑞將停止對丹納格列波隆的所有測試，包括其與其他藥物聯合用於肥胖症治療的測試。Even with recent price cuts, many of these medications still cost hundreds of dollars per month.即使近期價格有所下調，許多此類藥物每月的費用仍高達數百美元。Pfizer had already stopped testing of a twice-daily version of danuglipron in late 2023 after more than half the people in a trial stopped taking it.輝瑞公司已於 2023 年底停止了每日兩次服用的丹那列普隆的測試，當時試驗中超過一半的人已停止服用該藥。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"SG9999002232.USD":"Allianz Global High Payout USD","BK4581":"高盛持仓","BK4599":"减肥药","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0122379950.USD":"贝莱德世界健康科学A2","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0234572021.USD":"高盛美国核心股票组合Acc","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","BK4592":"伊斯兰概念","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0058720904.USD":"联博国际健康护理基金A","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","BK4568":"美国抗疫概念","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","PFE":"辉瑞","BK4588":"碎股","BK4550":"红杉资本持仓","SG9999001176.USD":"United Global Healthcare Acc USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","BK4007":"制药","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus"},"translate_title":"Pfizer halts diet pill test over potential liver damage Pfizer Ends Testing of Obesity Pill After Possible Liver Injury","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":1},"content_text":"TUESDAY, April 15, 2025 — Pfizer has stopped developing a once-daily pill to treat obesity after a person in a clinical trial showed signs of a possible liver injury.2025年4月15日，星期二——輝瑞公司停止了一種每日一次的治療肥胖症藥物的開發，因為一名臨牀試驗參與者顯示出可能的肝損傷跡象。The company said the injury went away after the person stopped taking the drug, called danuglipron,公司表示，該人士停止服用名為danuglipron的藥物後，傷害消失了。The Associated Press美聯社reported.已報告。The pill was in early testing to help determine the best dose, according to a Pfizer spokeswoman.據輝瑞公司發言人稱，該藥片正處於早期測試階段，以幫助確定最佳劑量。The company had planned to move the drug into late-stage trials, typically the final step before review by the U.S. Food and Drug Administration (FDA).公司原計劃將該藥物投入後期試驗，這通常是提交美國食品和藥物管理局 (FDA) 審查前的最後一步。Pfizer will now stop all testing of danuglipron, including its use with other drugs for obesity treatment. However, the company said it still plans to work on other obesity treatments that are in earlier stages of research.輝瑞將停止對丹納格列波隆的所有測試，包括其與其他藥物聯合用於肥胖症治療的測試。然而，該公司表示仍計劃繼續研究其他處於早期階段的肥胖症治療方法。Obesity drugs have become a major focus for pharmaceutical companies. Injectable treatments like Eli Lilly’s肥胖症藥物已經成為製藥公司的主要關注點。像禮來公司（Eli Lilly）的可注射治療藥物等。Zepbound澤普綁定and Novo Nordisk’s諾和諾德的Wegovy韋哥維have brought in billions in revenue. Zepbound earned nearly $5 billion in 2024 alone,帶來了數十億美元的收入。僅2024年，Zepbound就賺了近50億美元，The Associated Press美聯社reported.據報道。But these drugs must be injected, which some folks don't want to do.但是這些藥物必須通過注射，有些人不想這樣做。As a result, drugmakers have been racing to develop pill versions. Lilly expects to release new data this year on two oral obesity drugs it is studying.因此，製藥商一直在競相開發藥片版本。禮來公司預計將在今年發布其正在研究的兩種口服減肥藥的新數據。While demand for these treatments is high, access has been an issue. Some patients face insurance issues or high out-of-pocket costs.雖然對這些治療的需求很高，但獲取途徑一直是個問題。一些患者面臨保險問題或高昂的自付費用。Even with recent price cuts, many of these medications still cost hundreds of dollars per month.即使近期價格有所下調，許多此類藥物每月的費用仍高達數百美元。Pfizer had already stopped testing of a twice-daily version of danuglipron in late 2023 after more than half the people in a trial stopped taking it.輝瑞公司已於 2023 年底停止了每日兩次服用的丹那列普隆的測試，當時試驗中超過一半的人已停止服用該藥。Whatever your topic of interest,無論你感興趣的話題是什麼，subscribe to our newsletters訂閲我們的新聞通訊to get the best of Drugs.com in your inbox.獲取 Drugs.com 的最新資訊到您的郵箱。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}